Skip to main navigation Skip to search Skip to main content

Guidelines for management of actual or suspected inadvertent intra-arterial injection of sclerosants

  • Kurosh Parsi*
  • , Marianne De Maeseneer
  • , Andre M. van Rij
  • , Christopher Rogan
  • , Wendy Bonython
  • , John A. Devereux
  • , Christopher K. Lekich
  • , Michael Amos
  • , Ahmet Kursat Bozkurt
  • , David E. Connor
  • , Alun H. Davies
  • , Sergio Gianesini
  • , Kathleen Gibson
  • , Peter Gloviczki
  • , Anthony Grabs
  • , Lorena Grillo
  • , Franz Hafner
  • , David Huber
  • , Mark Iafrati
  • , Mark Jackson
  • Ravul Jindal, Adrian Lim, Fedor Lurie, Lisa Marks, Pauline Raymond-Martimbeau, Peter Paraskevas, Albert Adrien Ramelet, Rodrigo Rial, Stefania Roberts, Carlos Simkin, Paul K. Thibault, Mark S. Whiteley
*Corresponding author for this work
  • International Union of Phlebology (UIP)
  • Australasian College of Phlebology (ACP)
  • St. Vincent's Hospital Sydney
  • University of New South Wales
  • St. Vincent’s Centre for Applied Medical Research (Darlinghurst)
  • University of Otago
  • Interventional Radiology Society of Australasia (IRSA)
  • Sydney Adventist Hospital
  • Macquarie University
  • Bond University
  • University of Queensland
  • Miami Private Hospital
  • Concord Repatriation General Hospital
  • Istanbul University
  • European College of Phlebology
  • St Mary's Hospital
  • University of Ferrara
  • Lake Washington Vascular Surgeons
  • Mayo Clinic Rochester, MN
  • University of Medical Sciences (UCIMED)
  • Medical University of Graz
  • Art of Vein Care
  • American Venous Forum (AVF)
  • Vanderbilt University School of Medicine
  • Australian and New Zealand Society for Vascular Surgery
  • Gold Coast Hospital and Health Service
  • Griffith University Queensland
  • Fortis Healthcare
  • Genesis Care and Royal North Shore Hospital
  • Jobst Vascular Institute
  • University of Michigan, Ann Arbor
  • Brighton Day Surgery
  • Dallas Non-Invasive Vascular Laboratory
  • Paras Clinic
  • University of Bern
  • University Hospital HM Madrid
  • Victoria Vein Clinic
  • Clínica Simkin
  • Central Vein and Cosmetic Medical Centre
  • The College of Phlebology
  • The Whiteley Clinic

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
357 Downloads (Pure)

Abstract

Background: 

Inadvertent intra-arterial injection of sclerosants is an uncommon adverse event of both ultrasound-guided and direct vision sclerotherapy. This complication can result in significant tissue or limb loss and significant long-term morbidity. 

Objectives: 

To provide recommendations for diagnosis and immediate management of an unintentional intra-arterial injection of sclerosing agents. Methods: An international and multidisciplinary expert panel representing the endorsing societies and relevant specialities reviewed the published biomedical, scientific and legal literature and developed the consensus-based recommendations. 

Results: 

Actual and suspected cases of an intra-arterial sclerosant injection should be immediately transferred to a facility with a vascular/interventional unit. Digital Subtraction Angiography (DSA) is the key investigation to confirm the diagnosis and help select the appropriate intra-arterial therapy for tissue ischaemia. Emergency endovascular intervention will be required to manage the risk of major limb ischaemia. This includes intra-arterial administration of vasodilators to reduce vasospasm, and anticoagulants and thrombolytic agents to mitigate thrombosis. Mechanical thrombectomy, other endovascular interventions and even open surgery may be required. Lumbar sympathetic block may be considered but has a high risk of bleeding. Systemic anti-inflammatory agents, anticoagulants, and platelet inhibitors and modifiers would complement the intra-arterial endovascular procedures. For risk of minor ischaemia, systemic oral anti-inflammatory agents, anticoagulants, vasodilators and antiplatelet treatments are recommended. 

Conclusion: 

Inadvertent intra-arterial injection is an adverse event of both ultrasound-guided and direct vision sclerotherapy. Medical practitioners performing sclerotherapy must ensure completion of a course of formal training (specialty or subspecialty training, or equivalent recognition) in the management of venous and lymphatic disorders (phlebology), and be personally proficient in the use of duplex ultrasound in vascular (both arterial and venous) applications, to diagnose and provide image guidance to venous procedure. Expertise in diagnosis and immediate management of an intra-arterial injection is essential for all practitioners performing sclerotherapy.

Original languageEnglish
Pages (from-to)683-719
Number of pages37
JournalPhlebology
Volume39
Issue number10
Early online date24 Jul 2024
DOIs
Publication statusPublished - Dec 2024

Bibliographical note

Publisher Copyright:
© The Author(s) 2024.

Fingerprint

Dive into the research topics of 'Guidelines for management of actual or suspected inadvertent intra-arterial injection of sclerosants'. Together they form a unique fingerprint.

Cite this